Ahmed Bouzidi, PhD, is the founder and Chief Executive Officer of Vaxeal Group, a leading SME pioneer in immuno-oncology. Ahmed is the actual President of the European Biopharmaceutical Enterprises (Brussels), the European Trade Association representing biopharmaceutical companies from innovative SMEs to worldwide leaders. He is also Senior Associate of the Royal Society of Medicine (London), and a board member of Vaccines Europe (Brussels). He previously founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based immunotherapies (exit by Leveraged Buy Out), and Biophysiomics inc. (acquired by Kuachang Science & Technology, China). He held senior advisory positions with high-level Chinese healthcare stakeholders (Public & Private Institutions), and worked for 10 years as a Senior Researcher at the LFB (France). Ahmed holds a Master degree in Animal Biology from University of Lille (France) and a PhD in Cellular Biology and an MBA from University of New Hampshire, Durham (USA).
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.